Bullish Case: DOCS has rebounded 33.6% off the July lows ($19.85→$26.51) while staying inside its documented mean-reverting regime; call volume exceeds puts by 47%; Helium's density puts peak mass at $25–27.5 with meaningful weight at $27.5–30; Oct Helium IV (48.5%) exceeds market (44.5%), implying the market underprices near-term drift higher; buyback capacity and Ask-benchmark AI leadership support a grind toward $30.

Bearish Case: The HeliumTrades AI forecast is -5.25% and the stock is still -64% YoY with weak bookings and EBITDA guidance diluted by AI spend. November IV (~72–76%) is nearly double October's (~44%), flagging a binary earnings event; market density carries fat left-tail mass at $17.5–20. A post-90-day-rebound fade is consistent with mean-reverting chop, not trend.

Potential Outcomes:

1. 40%: Range $24–29 into October expiry; falsified by weekly close outside band.
2. 25%: Earnings-driven gap (Nov 21 cycle) pushing to $30–33 on bookings beat; falsifiable by IV crush with price <$26 after the print.
3. 20%: Fade to $21–24 as AI monetization skepticism and pharma budgets reassert; falsified by sustained closes >$27.
4. 10%: Renewed slide <$20 with IV spike >90%; falsifiable if realized vol stays below implied.
5. 5%: Buyback/M&A catalyst >$35; falsifiable via SEC filings silence through Q1 2027.

September 23, 2026